[{"AccountsPayableCurrent_0_Q2_USD":10087000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":-3000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":-95000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2_Q2_USD":86000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1_Q2_USD":-92000.0,"OtherAssetsNoncurrent_0_Q2_USD":3813000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.128,"OperatingLeasePayments_2_Q2_USD":819000.0,"OperatingLeaseExpense_2_Q2_USD":913000.0,"OperatingIncomeLoss_2_Q2_USD":-80959000.0,"OperatingIncomeLoss_1_Q2_USD":-29582000.0,"NotesPayableCurrent_0_Q2_USD":30000000.0,"NetIncomeLoss_2_Q2_USD":-107482000.0,"NetIncomeLoss_1_Q2_USD":-43198000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-86422000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":19177000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":7474000.0,"LongTermDebtNoncurrent_0_Q2_USD":126796000.0,"LiabilitiesCurrent_0_Q2_USD":115601000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":277284000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":5891000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":606000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":834000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":655000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":581000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":969000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":-2000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":10972000.0,"PaidInKindInterest_2_Q2_USD":7459000.0,"PaymentsToAcquireProductiveAssets_2_Q2_USD":912000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":4574000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q2_USD":7632000.0,"StockholdersEquity_0_Q2_USD":-106075000.0,"ShareBasedCompensation_2_Q2_USD":13111000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":48439000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":26325000.0,"RevenueFromContractWithCustomerIncludingAssessedTax_2_Q2_USD":69018000.0,"RevenueFromContractWithCustomerIncludingAssessedTax_1_Q2_USD":49959000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-1130924000.0,"RestrictedCashAndCashEquivalentsAtCarryingValue_0_Q2_USD":4348000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":95308000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":52873000.0,"ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_2_Q2_USD":1000.0,"ReceivablesNetCurrent_0_Q2_USD":6513000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":7669000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":7474000.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2_Q2_USD":20089000.0,"ProceedsFromIssuanceOfWarrants_2_Q2_USD":0.0,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":0.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":5560000.0,"PreferredStockValue_0_Q2_USD":0.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"PreferredStockSharesAuthorized_0_Q2_shares":5000000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_2_Q2_USD":0.0,"InventoryWorkInProcess_0_Q2_USD":4597000.0,"InventoryValuationReserves_0_Q2_USD":270000.0,"InventoryRawMaterials_0_Q2_USD":4990000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-43293000.0,"CommonStockValue_0_Q2_USD":1787000.0,"CommonStockSharesOutstanding_0_Q2_shares":178725000.0,"CommonStockSharesIssued_0_Q2_shares":178725000.0,"CommonStockSharesAuthorized_0_Q2_shares":450000000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.01,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-59686000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":214662000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":210314000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":8114000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":8114000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":8111000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":0.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":1000.0,"AssetsCurrent_0_Q2_USD":265802000.0,"Assets_0_Q2_USD":277284000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":25871.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q2_shares":27419.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":13111000.0,"AdvertisingExpense_2_Q2_USD":3204000.0,"AdvertisingExpense_1_Q2_USD":1800000.0,"AdditionalPaidInCapital_0_Q2_USD":1022975000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":87000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":48765000.0,"AccountsReceivableNetCurrent_0_Q2_USD":27620000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-107398000.0,"CostOfGoodsAndServicesSold_1_Q2_USD":297000.0,"CostOfGoodsAndServicesSold_2_Q2_USD":6220000.0,"CostsAndExpenses_1_Q2_USD":79541000.0,"InventoryNet_0_Q2_USD":9846000.0,"InventoryGross_0_Q2_USD":10116000.0,"InventoryFinishedGoods_0_Q2_USD":529000.0,"InterestPayableCurrent_0_Q2_USD":25217000.0,"InterestExpenseDebt_2_Q2_USD":26399000.0,"InterestExpenseDebt_1_Q2_USD":13495000.0,"InterestExpense_2_Q2_USD":26399000.0,"InterestExpense_1_Q2_USD":13495000.0,"IncreaseDecreaseInReceivables_2_Q2_USD":18976000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":34000.0,"IncreaseDecreaseInInventories_2_Q2_USD":2809000.0,"IncreaseDecreaseInInterestPayableNet_2_Q2_USD":3547000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":178127.0,"IncreaseDecreaseInDerivativeAssets_2_Q2_USD":0.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":2743000.0,"GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_2_Q2_USD":-163000.0,"GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_1_Q2_USD":-134000.0,"FinanceLeaseLiabilityNoncurrent_0_Q2_USD":4100000.0,"FinanceLeaseLiabilityCurrent_0_Q2_USD":981000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0_Q2_USD":60067000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_Q2_USD":85000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-600.0,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-240.0,"DepreciationDepletionAndAmortization_2_Q2_USD":377000.0,"DeferredRevenueCurrent_0_Q2_USD":551000.0,"CostsAndExpenses_2_Q2_USD":149977000.0,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":403000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":177737.0,"Ticker":"BCRX","CIK":"882796","name":"BIOCRYST PHARMACEUTICALS INC","OfficialName":"BioCryst Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1887243586.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20210809"}]